We are a development-stage biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other devastating disorders for which no disease-modifying treatments exist.
Our pioneering approach using ANTISENILIN® monoclonal antibodies to reduce beta amyloid toxicity in the brain of Alzheimer's disease has gained considerable momentum over the past few years and leading experts in the field have expressed optimism that drugs being developed using the company's proprietary patented technology herald an exciting new era of drug development for safe and efficacious disease modifying treatments for Alzheimer's disease.

We have a assembled a diversified product pipeline with drug candidates in preclinical and clinical development and a scientific team focused on drug discovery to address important unmet medical needs in Alzheimer's disease and other neurodegenerative and aging disorders, such as Parkinson's disease, Huntington's disease and Glaucoma among others.

We believe that our scientific approach, technology platforms and unique ability to leverage our pivotal patent position by granting licenses of our monoclonal antibodies patents to major pharmaceutical companies with drug products in clinical development provide us a strong competitive advantage.